ACADIA PHARMACEUTICALS INC — Director's Dealing 2013

Jun 5, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2013-06-03

Reporting Person: BAKER FELIX (Director, 10% Owner)
Reporting Person: BAKER JULIAN (Director, 10% Owner)
Reporting Person: BAKER BROS ADVISORS LLC (Director, 10% Owner)
Reporting Person: 667, L.P. (Director, 10% Owner)
Reporting Person: 14159, L.P. (Director, 10% Owner)
Reporting Person: Baker Brothers Life Sciences LP (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-06-03	Common Stock	P	56274	$14.0822	Acquired	1320595	Indirect
2013-06-03	Common Stock	P	461548	$14.0822	Acquired	16422130	Indirect
2013-06-03	Common Stock	P	11511	$14.0822	Acquired	401420	Indirect
2013-06-03	Common Stock	P	25368	$13.999	Acquired	1345963	Indirect
2013-06-03	Common Stock	P	208063	$13.999	Acquired	16630193	Indirect
2013-06-03	Common Stock	P	5189	$13.999	Acquired	406609	Indirect
2013-06-04	Common Stock	P	4353	$14.4977	Acquired	1350316	Indirect
2013-06-04	Common Stock	P	35702	$14.4977	Acquired	16665895	Indirect
2013-06-04	Common Stock	P	890	$14.4977	Acquired	407499	Indirect
2013-06-04	Common Stock	P	56475	$14.4525	Acquired	1406791	Indirect
2013-06-04	Common Stock	P	463197	$14.4525	Acquired	17129092	Indirect
2013-06-04	Common Stock	P	11552	$14.4525	Acquired	419051	Indirect
2013-06-04	Common Stock	P	13566	$14.4159	Acquired	1420357	Indirect
2013-06-04	Common Stock	P	111266	$14.4159	Acquired	17240358	Indirect
2013-06-04	Common Stock	P	2775	$14.4159	Acquired	421826	Indirect
2013-06-05	Common Stoc	P	26577	$14.4565	Acquired	1446934	Indirect
2013-06-05	Common Stoc	P	217986	$14.4565	Acquired	17458344	Indirect
2013-06-05	Common Stoc	P	5437	$14.4565	Acquired	427263	Indirect
2013-06-05	Common Stoc	P	21080	$14.5838	Acquired	1468014	Indirect
2013-06-05	Common Stoc	P	172893	$14.5838	Acquired	17631237	Indirect
2013-06-05	Common Stoc	P	4312	$14.5838	Acquired	431575	Indirect
2013-06-05	Common Stoc	P	18530	$14.5502	Acquired	1486544	Indirect
2013-06-05	Common Stoc	P	151980	$14.5502	Acquired	17783217	Indirect
2013-06-05	Common Stoc	P	3790	$14.5502	Acquired	435365	Indirect
2013-06-05	Common Stoc	P	26577	$14.4641	Acquired	1513121	Indirect
2013-06-05	Common Stoc	P	217986	$14.4641	Acquired	18001203	Indirect
2013-06-05	Common Stoc	P	5437	$14.4641	Acquired	440802	Indirect

Footnotes

F1: After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by 667, L.P. ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F2: The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $13.70 to $14.52, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3: After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Baker Brothers Life Sciences. L.P. ("Life Sciences"), a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F4: The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $13.70 to $14.52, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F5: After giving effect to the transactions reported herein and as a result of their ownership interest in 14159 Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in Column 5 of Table I directly held by 14159, L.P ("14159", and together with Baker Tisch, Baker Bros. Investments, Baker Bros. Investments II, 667 and Life Sciences, the "Funds"), a limited partnership of which the sole general partner is 14159 Capital L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital L.P.'s right to receive an allocation of a portion of the profits from 14159.

F6: The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $13.70 to $14.52, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F7: The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $13.70 to $14.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F8: The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $13.70 to $14.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F9: The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $13.70 to $14.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F10: The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.36 to $14.59, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F11: The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.36 to $14.59, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F12: The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.36 to $14.59, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F13: The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.12 to $14.83, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F14: The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.12 to $14.83, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F15: The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.12 to $14.83, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F16: The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.18 to $14.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F17: The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.18 to $14.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F18: The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.18 to $14.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F19: The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.28 to $14.60, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F20: The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.28 to $14.60, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F21: The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.28 to $14.60, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F22: The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.29 to $14.78, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F23: The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.29 to $14.78, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F24: The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.29 to $14.78, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F25: The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.37 to $14.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F26: The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.37 to $14.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F27: The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.37 to $14.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F28: The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.30 to $14.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F29: The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.30 to $14.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F30: The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.30 to $14.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F31: The aggregate indirect beneficial ownership reported on this form is 19,955,126 shares.

F32: Baker Bros. Advisors, LLC (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Julian C. Baker and Felix J. Baker are principals of the Adviser. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.